This healthcare platform offers diagnostic tools and therapeutic products focused on heart and cardiovascular diseases. Their technology helps individuals assess their risk of heart attack and manage related conditions.
Funding
$100K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing cardiovascular disease (CVD) risk and managing clotting and inflammation may not accurately identify individuals at high risk, leading to ineffective treatment strategies. Existing biomarkers may lack the stability and specificity needed for precise risk stratification, potentially resulting in unnecessary or inadequate interventions. This is especially critical in acutely ill patients and surgical patients who are at higher risk of clotting.
Solution
Gamma Diagnostics offers the GammaCoeur™ CVD Risk ELISA Test System, a semi-automated quantitative assay for detecting and measuring Gamma Prime Fibrinogen (GPF) levels in human plasma. GPF is a fibrinogen isoform that serves as a biomarker for clotting and inflammation, offering a more stable and indicative measure compared to traditional markers. The GammaCoeur™ test helps clinicians identify patients at risk of CVD, including those with hypertension, increased BMI, diabetes, a history of smoking, or a family history of CVD. By measuring GPF levels, the test enables physicians to make informed decisions about thrombolytic treatment, potentially improving patient outcomes and survival, especially since GPF-rich clots are resistant to lysis by traditional strategies like heparin.
Target Audience
The primary target audience includes clinical and research laboratories, as well as clinicians assessing CVD risk in adults with conditions such as hypertension, increased BMI, diabetes, history of smoking, or family history of CVD.
Features
- Semi-automated quantitative ELISA method for GPF detection in human plasma
- Utilizes a two-site sandwich immunoassay with monoclonal capture antibody
- Measures the gamma-prime fibrinogen isoform
- Demonstrated association between GPF concentrations and prevalent coronary artery disease, myocardial infarction, stroke, and inflammation
- GPF is up to 6x more stable than hs-CRP
- Applicable to multiple diseases, including CVD and COVID-19
- CE Marked